Literature DB >> 33220154

The NAFLD-MAFLD debate: Eminence vs evidence.

Yasser Fouad1, Reda Elwakil2, Medhat Elsahhar3, Ebada Said4, Shamardan Bazeed5, Ahmed Ali Gomaa6, Almoutaz Hashim7, Enas Kamal1, Mai Mehrez8, Dina Attia9.   

Abstract

Debates are inevitable in science and could be a powerful tool for addressing controversial topics as it promotes critical thinking and inspires individuals to consider alternate viewpoints. However, debates can help only to identify the issues that need to be clarified to address this question, but it can never help resolve the controversy itself. In the era of evidence-based medicine, the need for an evidence-based debate is mandatory. Polarising opinions and major debate have recently arisen in hepatology on the nomenclature and diagnostic criteria for fatty liver disease associated with metabolic dysfunction (non alcoholic fatty liver disease [NAFLD]-metabolic (dysfunction) associated fatty liver disease [MAFLD] debate). The aim of this viewpoint is to suggest a way to settle the debate through evidence. Descriptive review using PubMed to identify literature on the evidence and eminence-based medicine and studies comparing MAFLD and NAFLD criteria. The emerging studies comparing the performance of diagnostic criteria of NAFLD and MAFLD represent the dawn of a new era for reframing the ongoing debate by acquisition of the mandatory evidence that will both resolve the debate and lead to novel avenues of research. In conclusion, the time has come to hold debate and focus on gathering and building the evidence to settle it. It does not matter who wins the debate and once there is robust evidence, we should all follow it wherever it leads.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MAFLD; NAFLD; debate; evidence.

Mesh:

Year:  2020        PMID: 33220154     DOI: 10.1111/liv.14739

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  20 in total

1.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 2.  Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.

Authors:  Mohammed Eslam; Hashem B El-Serag; Sven Francque; Shiv K Sarin; Lai Wei; Elisabetta Bugianesi; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-06-16       Impact factor: 73.082

3.  Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia.

Authors:  Belinda Varaidzo Chihota; Carlotta Riebensahm; Guy Muula; Edford Sinkala; Roma Chilengi; Lloyd Mulenga; Samuel Bosomprah; Michael J Vinikoor; Carolyn Bolton-Moore; Matthias Egger; Andri Rauch; Annalisa Berzigotti; Gilles Wandeler
Journal:  BMJ Open Gastroenterol       Date:  2022-07

4.  Relationship between the Metabolic Associated Fatty Liver Disease and Endometrial Thickness in Postmenopausal Women: A Cross-sectional Study in China.

Authors:  Jia-Ying Wei; Zhou Xu; Hao Li; Wen-Qin Du; Bai-Ling Niu; Shu Li; Shen Tian; Juan Wu; Yu-Ling Chen; Xin Li; Zi-Li Liu; Jun Xiao; Guo-Sheng Ren; Liang Ran; Ling-Quan Kong
Journal:  Int J Med Sci       Date:  2021-06-22       Impact factor: 3.738

5.  State of Sweat: Emerging Wearable Systems for Real-Time, Noninvasive Sweat Sensing and Analytics.

Authors:  Roozbeh Ghaffari; Da Som Yang; Joohee Kim; Amer Mansour; John A Wright; Jeffrey B Model; Donald E Wright; John A Rogers; Tyler R Ray
Journal:  ACS Sens       Date:  2021-08-05       Impact factor: 9.618

Review 6.  Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.

Authors:  Yasser Fouad; Melissa Palmer; Minjun Chen; Arie Regev; Rajarshi Banerjee; Rob Myers; Robert Riccio; Richard Torstenson; Ramy Younes; Puneet S Arora; Henrik Landgren; Morten A Karsdal; Martin Blake; David A Shapiro; Hans-Juergen Gruss; Muhammad Y Sheikh; Dina Attia; Steven Bollipo; Alastair D Smith; Bradley Freilich; Robert G Gish; Detlef Schuppan
Journal:  J Clin Transl Hepatol       Date:  2021-10-22

7.  NAFLD and MAFLD as emerging causes of HCC: A populational study.

Authors:  Shuna Myers; Isabelle Neyroud-Caspar; Laurent Spahr; Konstantinos Gkouvatsos; Evelyne Fournier; Emiliano Giostra; Giulia Magini; Jean-Louis Frossard; Marie-Eve Bascaron; Nathalie Vernaz; Lucia Zampaglione; Francesco Negro; Nicolas Goossens
Journal:  JHEP Rep       Date:  2021-01-19

8.  MAFLD progression contributes to altered thalamus metabolism and brain structure.

Authors:  Saverio Nucera; Stefano Ruga; Antonio Cardamone; Anna Rita Coppoletta; Lorenza Guarnieri; Maria Caterina Zito; Francesca Bosco; Roberta Macrì; Federica Scarano; Miriam Scicchitano; Jessica Maiuolo; Cristina Carresi; Rocco Mollace; Luca Cariati; Giuseppe Mazzarella; Ernesto Palma; Micaela Gliozzi; Vincenzo Musolino; Giuseppe Lucio Cascini; Vincenzo Mollace
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.996

Review 9.  Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Authors:  Jianan Zhao; Yu Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-07-07       Impact factor: 5.787

10.  MAFLD in Obese Children: A Challenging Definition.

Authors:  Anna Di Sessa; Stefano Guarino; Giuseppina Rosaria Umano; Mattia Arenella; Salvatore Alfiero; Gaetano Quaranta; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  Children (Basel)       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.